Celularity Closes $10M Initial Funding in $28M Recapitalization Plan

Key Facts

1Celularity closed an initial financing of over $10 million as part of a recapitalization plan totaling up to $28 million.

2The company aims to achieve positive operating cash flow by the first quarter of 2027.

In a move reflecting the ongoing efforts of biotech firms to fortify their balance sheets, Celularity Inc. has announced the closing of an initial financing round exceeding $10 million. This funding is a core component of a broader $28 million recapitalization strategy designed to accelerate growth and optimize the company's financial structure. According to reports, the company aims to leverage this capital to achieve positive operating cash flow by the first quarter of 2027.

The recapitalization plan combines new cash investments with the management of existing liabilities, including the restructuring of approximately $3 million in current debt. These financial maneuvers follow significant operating improvements, such as a reduction in monthly cash burn and a strategic shift toward revenue-generating opportunities. The company remains focused on converting its scientific assets and manufacturing infrastructure into sustained growth per analyst facts.

Regarding market performance, CELU stock stood at $1.15 (close September 23, 2026), having traded between a day low of $1.13 and a high of $1.18 according to market data. Investors are monitoring the company's progress toward its 2027 cash-flow targets, while broader sector sentiment may be influenced by recent macroeconomic indicators such as the U.S. Industrial Production figures reported earlier this month.